Greg K. Sakamoto, MD

Eruptive Keratoacanthomas After Nivolumab Treatment of Stage III Melanoma

Publish date: May 17, 2023

Eruptive keratoacanthomas (KAs) are a rare buttransient adverse effect of programmed cell death protein 1 (PD-1) inhibitor therapy.